Affiliation:
1. Departments of Obstetrics and Gynaecology and School of Population and Public Health, University of British Columbia and British Columbia's Women's Hospital and Health Centre, Vancouver, British Columbia, Canada
2. Pediatrics, Dalhousie University and the Izaak Walton Killam Health Centre, Halifax, Canada
Abstract
OBJECTIVE: We studied patterns of prenatal corticosteroid use, respiratory distress syndrome, and associated mortality rates to assess the congruence between knowledge and clinical practice related to such prophylaxis.
METHODS: We used data on all live births in the United States (for the years 1989–1991, 1995–1997, and 2002–2004) and Nova Scotia, Canada (for the years 1988–2007). Gestational age-specific temporal trends in infant deaths resulting from respiratory distress syndrome were quantified in the United States, and gestational age-specific temporal trends in corticosteroid use and morbidity (respiratory distress syndrome and intraventricular hemorrhage) were quantified in Nova Scotia.
RESULTS: In the United States, infant deaths associated with respiratory distress syndrome decreased by 48% (95% confidence interval: 46%–50%) from 1989–1991 to 1995–1997 and then decreased by another 18% (95% confidence interval: 15%–22%) by 2002–2004. The latter mortality reduction was evident at 28 to 32 weeks but not 33 to 36 weeks of gestation. Corticosteroid use at 28 to 32 weeks was high in Nova Scotia and increased from 30.7% in 1988–1989 to 50.0% in 1996–1997 and to 52.9% in 2006–2007, whereas rates of use at 33 to 36 weeks were much lower (eg, 6.7%, 17.0%, and 15.7% at 34 weeks in the 3 periods). Increased corticosteroid use at 33 and 34 weeks was estimated to reduce respiratory distress syndrome substantially.
CONCLUSION: Addressing the knowledge-practice gap in corticosteroid use at 33 to 34 weeks should reduce infant morbidity and mortality rates.
Publisher
American Academy of Pediatrics (AAP)
Subject
Pediatrics, Perinatology and Child Health
Reference31 articles.
1. National Institute of Child Health and Human Development. Effect of corticosteroids for fetal maturation on perinatal outcomes. NIH Consens Statement. 1994;12(2):1–24
2. American College of Obstetricians and Gynecologists, Committee on Obstetric Practice. Committee Opinion 147: antenatal corticosteroid therapy for fetal maturation. Int J Gynaecol Obstet. 1995;48(3):340–342
3. National Institutes of Health. Antenatal corticosteroids revisited: repeat courses. NIH Consens Statement. 2000;17(2):1–10
4. Roberts D, Dalziel S. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev. 2006;(3):CD004454
5. Cunningham FG, Gant NF, Leveno KJ, Gilstrap LC III, Hauth JC, Wenstrom KD, eds. Williams Obstetrics. 21st ed. Toronto, Canada: McGraw-Hill; 2001
Cited by
30 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献